Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04316975

Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Barretts Esophagus With Dysplasia Clinical Trial

Official title:
Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Clinical Trial Summary

To evaluate association between mutational load (ML) from esophageal biopsy specimens in pre-endoscopic eradication therapy (EET) in Barrett's Esophagus (BE) or Intramucosal adenocarcinoma (IMC) patients and treatment resistance (treatment resistance will be defined as disease recurrence and/or need for additional intervention such as increased acid suppression, need for anti-reflux surgery, or use of alternate ablative modality).

Clinical Trial Description

Potential subjects will be identified via protocol and Institutional Review Board (IRB) methods prior to obtaining written informed consent. Once written informed consent is obtained, subjects will continue with planned routine care upper endoscopy. During the first study visit an upper endoscopy will be performed. At this visit, research specimens will be obtained for mutational load (ML) analysis and gastroenterologist (GI) pathologist diagnosis for the presence of adenocarcinoma or degrees of dysplasia. ML will be correlated to the pathology diagnosis on this research biopsy. Subjects will then undergo EET per routine standard of care at the treating institution until CEIM achieved. Subjects will be followed (data collection only) during treatment period until CEIM is achieved. After subjects reach CEIM, four additional research biopsies will be collected, from the midpoint of previous BE site. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04316975
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date April 10, 2020
Completion date December 20, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05530343 - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance N/A
Recruiting NCT06071845 - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples N/A
Recruiting NCT04001478 - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed NCT03685799 - Impact of Histologic Concordance Between Biopsies and the Endoscopic Resection Specimen, in the Treatment of Barrett's Esophagus in Dysplasia, on the Recurrence of Dysplasia
Recruiting NCT04295811 - Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC N/A
Not yet recruiting NCT04843397 - Diagnostic Performance Indicators in Upper GI Endoscopy:PROSPERO Study
Completed NCT03120195 - EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study N/A
Recruiting NCT05753748 - Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia N/A
Enrolling by invitation NCT04561791 - Evaluation of Tethered Capsule Endomicroscopy as a Screening Tool for Barrett's Esophagus in the Primary Care Setting N/A
Completed NCT04293458 - Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE N/A
Recruiting NCT06030180 - CLUE: CLinical Utility Study of EsoGuard N/A
Active, not recruiting NCT02994693 - Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
Not yet recruiting NCT05276791 - EMR Versus ESD for Barrett's Neoplasia N/A
Completed NCT03193216 - The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus Phase 2
Recruiting NCT05983419 - Complete Resection of Barrett's Esophagus Harboring Neoplasia With Endoscopic Submucosal Dissection. N/A
Completed NCT06381583 - A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
Recruiting NCT05965999 - Lucid Registry Study